|
|
BOON IN THE FIGHT AGAINST PROSTATE CANCER PATIENTS
ZYTIGAtm (abiraterone acetate) RECEIVES FDA APPROVAL
DENVER -The U.S. Food and Drug Administration approved ZYTIGA today, a once-daily, oral medication used in the treatment of certain men with advanced prostate cancer.
Prostate cancer is the most prevalent form of cancer among American males. More than 220,000 will be diagnosed with prostate cancer this year and 32,000 men will die from the disease. Young men aged 35 to 44 have been found to have the highest percentage of advanced (metastatic) disease and risk of death. In addition, African American men are 1.6 times as likely to be diagnosed with prostate cancer and 2.4 times as likely to die of this disease.
For over a decade, limited treatments have been available for men with advanced prostate cancer. New therapies like ZYTIGA, not only provide a significant improvement in survival and quality of life for patients but also provide hope to men and their families.
"Prostate cancer is a significant public health threat in the United States," said Wendy L. Poage, MHA, President of the Prostate Conditions Education Council (PCEC). "ZYTIGA is a welcomed addition to the arsenal we have to fight this deadly disease."
Phase 3 clinical trials with ZYTIGA and prednisone showed a significant increase in median survival compared with a placebo and prednisone. Clinical trail data show a 35% reduction in the risk of death and up to a 4.6-month median survival advantage. ZYTIGA is indicated, in combination with prednisone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel.
For more information, contact the Prostate Conditions Education Council at 866-4PROST8 (866-477-6788.
|
|
Light the White House Blue
Make sure that prostate cancer gets the coverage it deserves! Follow the link below and sign the petition to Light the White House Blue during September 2011 for Prostate Cancer Awareness Month!
Petition to Light the White House Blue
|
|
LAST DAY TO COMMENT
TIME IS RUNNING OUT to COMMENT and ensure all eligible men have access to it before the final determination is made.
| The Centers for Medicare and Medicaid Services (CMS) proposes that the
evidence is adequate to conclude that the use of autologous cellular
immunotherapy treatment - sipuleucel-T; PROVENGE(r) improves health outcomes for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer, and thus is reasonable and necessary for that indication under 1862(a)(1)(A) of the Social Security Act (the Act).
While this ruling is a huge victory in getting Provenge covered for Medicare patients, there is still discussion over the eligibility of Medicare recipients. Medicare approved the drug using the criteria from the clinical trial which eliminates many sub categories of men who could benefit frompopulatons o. Many patients and healthcare providers would like to make certain that the eligibility and access be expanded to be more inclusive.
"Medicare said it received 657 public comments during its deliberations over Provenge, of which 620, or 94.4 percent, were in favor of it paying for the drug."
They listen to your comments! Follow the link below to comment and make sure that access to this great drug is broadened!
CMS government Website...go to COMMENT |
|
Prostate Cancer Awareness Week
September 18-25, 2011
| |
PCEC's Early Detection and Awareness Program has been busy supporting spring health fairs and other men's health screening events this year! We are also gearing up for Prostate Cancer Awareness Week in September! We are currently accepting registration forms for your Prostate Health Screening Event! If you do not have one, please call 303.316.4685 and we will be happy to email or fax one to you!
PCEC strives to educate men and the people in their lives on Prostate Health. The need is still strong and we have many tough battles ahead. Let's work together, to spread the word about the prevalence of Prostate Health issues, the importance of early detection and the availability of treatment options. With your continued hard word and dedication on hosting Prostate Health Screening Events, we have reached millions of men with our important messaging on Prostate Health and awareness and we sincerely, thank you!
|
Attending AUA 2011 5/14 - 5/19 in Washington DC?
List of Abstracts that PCEC funded...
| |
Tuesday, May 17, 2011 - Benign Prostatic Hyperplasia: Basic Research 10:30 AM - 12:30 PM Session - Washington Convention Center, 206
- ID 1583 - AMERICAN UROLOGICAL ASSOCIATION SYMPTOM SCORE NOCTURIA QUESTION AS AN INDEPENDENT INDICATOR OF BPH IN A SCREENING POPULATION
Wednesday, May 18, 2011 - Prostate Cancer: Detection and Screening II 8:00 AM - 10:00 AM - Washington Convention Center, 206
- ID 2042 - Prostate Cancer and Men's Health Screening: Comparison of the Screening Populations from 2003-2009
|
|
7009 S. Potomac Street, Suite 125 * Centennial, CO 80112 www.prostateconditions.org |
|
|
| SET the PACE for Prostate Cancer 5K Run/Walk & 1 Mile Fun Walk
Saturday, June 18th
Stapleton Central Park
Denver, CO
Celebrate Father's Day Weekend and National Mens Health Week with us! | |
Register for the Run or get more information!
|
 | |
Want to do more for Prostate Cancer Awareness?
We are looking for individuals and companies to join our SET the PACE Series and host an event! We will assist the development from start to finish.
Your successful run, bicycle ride or other fundraising event with increase awareness of prostate cancer, educate men and their families on the importance of early detection, provide creative marketing for your company and best of all, keep proceeds local.
For More Information on Hosting an Event
| | |
| National Council Physicians | E. David Crawford, M.D.
University of Colorado
David G. McLeod, M.D Walter Reed Army
Neal Shore, M.D.
Grand Strand Urology
Frank Staggers, M.D.
NMA
Nelson N. Stone, M.D.
Mount Sinai
Allan Partin, M.D.
Johns Hopkins
Daniel Petrylak, M.D.
Columbia-Presbyterian
Mark Moyad, M.D.
University of Michigan
Mack Roach, M.D.
University of Calif. SF
Michael Lutz, M.D
Michigan Urology Inst.
|
|
|
